TriangleEmapalumab (NCT06996119)
Emapalumab trial for AML or MDS Undergoing Reduced-Intensity Transplant (NCT06996119). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with acute myeloid leukemia or myelodysplastic syndrome who are having a reduced intensity donor stem cell transplant.
The idea: graft versus host disease happens when donor immune cells attack the patient's body. This study adds emapalumab, an antibody that blocks interferon gamma, to the usual medicines given after transplant to prevent it: cyclophosphamide, tacrolimus, and mycophenolate mofetil.
The study looks at safety and whether this lowers graft versus host disease.
This phase 1 study plans 15 patients. At City of Hope in Duarte, California, Amandeep Salhotra leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.